{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T14:04:59Z","timestamp":1784901899496,"version":"3.55.0"},"reference-count":50,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"unspecified","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"National Clinical Research Center for Otolaryngologic Diseases","award":["2024KF018"],"award-info":[{"award-number":["2024KF018"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,7,14]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"\n Background<\/jats:title>\n Optimal induction chemoimmunotherapy sequential concurrent chemoradiotherapy (cCRT) in locally advanced hypopharyngeal squamous cell carcinoma (HSCC) remains undefined. This study aimed to evaluate toripalimab plus chemotherapy sequential cCRT with nimotuzumab, followed by toripalimab maintenance in unresectable stage IVB HSCC.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n In this single-arm, open-label, phase 2 study, untreated patients received two 21-day cycles of induction toripalimab 240\u2009mg (d1) plus\n nab<\/jats:italic>\n -paclitaxel 230 mg\/m\n 2<\/jats:sup>\n (d1) and cisplatin\/nedaplatin 40 mg\/m\n 2<\/jats:sup>\n (d1-2) sequential cCRT (helical tomotherapy;\n nab<\/jats:italic>\n -paclitaxel 230 mg\/m\n 2<\/jats:sup>\n (d1, 22, 43)) with nimotuzumab 200\u2009mg weekly for 7 weeks. Subsequently, toripalimab maintenance was administered for eight cycles. Primary endpoint was progression-free survival (PFS).\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n From March 16, 2022 to April 24, 2024, 31 patients completed induction chemoimmunotherapy. With a median follow-up of 31 months, median PFS and overall survival (OS) were not reached; 2-year PFS and OS rates were 67.7% and 86.4%. The 2-year larynx preservation rate was 93.3%. 30 (96.8%) patients achieved the best objective response, with 28 (90.3%) complete responses and 2 (6.5%) partial responses. The most common grade 3\u20134 treatment-related adverse events (TRAEs) were radiation-induced oropharyngeal mucositis and decreased appetite (each 46.9%). No grade 5 and fatal TRAEs occurred. No difficulties in speech and swallowing functions were reported in 96.8% of patients. There was no significant association between PFS and PD-L1 combined positive score, epidermal growth factor receptor expression, tumor-infiltrating T-lymphocytes, tumor mutational burden, or genetic alterations. High baseline peripheral CD3\n +<\/jats:sup>\n and CD8\n +<\/jats:sup>\n CD28\n +<\/jats:sup>\n T-cell levels were associated with favorable PFS. Exploratory biomarker analyses identified that patients without disease progression after maintenance exhibited significantly higher levels of CD8\n +<\/jats:sup>\n CD28\u207b T cells with a memory phenotype and lower B-cell levels.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n This exploratory study demonstrated preliminary efficacy and larynx preservation with manageable toxicity, possibly supporting further evaluation of induction toripalimab plus chemotherapy sequential cCRT with nimotuzumab, followed by toripalimab maintenance in stage IVB HSCC. Peripheral lymphocytes may warrant further investigation as candidate biomarkers in locally advanced disease.<\/jats:p>\n <\/jats:sec>\n \n Trial registration number<\/jats:title>\n \n NCT05860335<\/jats:ext-link>\n ; ChiCTR2300074672.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1136\/jitc-2026-015325","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:20:24Z","timestamp":1784899224000},"page":"e015325","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Induction toripalimab plus chemotherapy sequential concurrent chemoradiotherapy with nimotuzumab followed by toripalimab maintenance in stage IVB hypopharyngeal squamous cell carcinoma: a single-arm phase 2 study"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct05860335","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05860335","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Zeyang","family":"Geng","sequence":"first","affiliation":[{"name":"Senior Department of Otolaryngology Head and Neck Surgery, The 6th Medical Center of Chinese PLA General Hospital, Chinese PLA Medical School, Beijing, China"},{"name":"National Clinical Research Center for Otolaryngologic Diseases, Beijing, China"},{"name":"State Key Laboratory of Hearing and Balance Science, Beijing, China"},{"name":"Key Laboratory of Hearing Science, Ministry of Education, Beijing, China"},{"name":"Beijing Key Laboratory of Hearing Impairment Prevention and Treatment, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanxiang","family":"Chen","sequence":"additional","affiliation":[{"name":"Senior Department of Otolaryngology Head and Neck Surgery, The 6th Medical Center of Chinese PLA General Hospital, Chinese PLA Medical School, Beijing, China"},{"name":"National Clinical Research Center for Otolaryngologic Diseases, Beijing, China"},{"name":"State Key Laboratory of Hearing and Balance Science, Beijing, China"},{"name":"Key Laboratory of Hearing Science, Ministry of Education, Beijing, China"},{"name":"Beijing Key Laboratory of Hearing Impairment Prevention and Treatment, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wei","sequence":"additional","affiliation":[{"name":"Senior Department of Otolaryngology Head and Neck Surgery, The 6th Medical Center of Chinese PLA General Hospital, Chinese PLA Medical School, Beijing, China"},{"name":"National Clinical Research Center for Otolaryngologic Diseases, Beijing, China"},{"name":"State Key Laboratory of Hearing and Balance Science, Beijing, China"},{"name":"Key Laboratory of Hearing Science, Ministry of Education, Beijing, China"},{"name":"Beijing Key Laboratory of Hearing Impairment Prevention and Treatment, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Liu","sequence":"additional","affiliation":[{"name":"Senior Department of Otolaryngology Head and Neck Surgery, The 6th Medical Center of Chinese PLA General Hospital, Chinese PLA Medical School, Beijing, China"},{"name":"National Clinical Research Center for Otolaryngologic Diseases, Beijing, China"},{"name":"State Key Laboratory of Hearing and Balance Science, Beijing, China"},{"name":"Key Laboratory of Hearing Science, Ministry of Education, Beijing, China"},{"name":"Beijing Key Laboratory of Hearing Impairment Prevention and Treatment, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Gu","sequence":"additional","affiliation":[{"name":"Senior Department of Otolaryngology Head and Neck Surgery, The 6th Medical Center of Chinese PLA General Hospital, Chinese PLA Medical School, Beijing, China"},{"name":"National Clinical Research Center for Otolaryngologic Diseases, Beijing, China"},{"name":"State Key Laboratory of Hearing and Balance Science, Beijing, China"},{"name":"Key Laboratory of Hearing Science, Ministry of Education, Beijing, China"},{"name":"Beijing Key Laboratory of Hearing Impairment Prevention and Treatment, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangnan","family":"Gou","sequence":"additional","affiliation":[{"name":"Department of Pathology, The First Medical Center of Chinese PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Liang","sequence":"additional","affiliation":[{"name":"Peking University Health Science Center, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0751-4808","authenticated-orcid":false,"given":"Liangliang","family":"Wu","sequence":"additional","affiliation":[{"name":"Laboratory of Oncology, The First Medical Center of Chinese PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinshu","family":"Sui","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Otolaryngologic Diseases, Beijing, China"},{"name":"Key Laboratory of Hearing Science, Ministry of Education, Beijing, China"},{"name":"Beijing Key Laboratory of Hearing Impairment Prevention and Treatment, Beijing, China"},{"name":"Department of Otolaryngology Head and Neck Surgery, College of Otolaryngology Head and Neck Surgery, Chinese PLA General Hospital, Chinese PLA Medical School, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luotong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology Head and Neck Surgery, College of Otolaryngology Head and Neck Surgery, Chinese PLA General Hospital, Chinese PLA Medical School, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, The First Medical Center of Chinese PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Chinese PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyi","family":"Liu","sequence":"additional","affiliation":[{"name":"Laboratory of Oncology, The First Medical Center of Chinese PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiming","family":"Yang","sequence":"additional","affiliation":[{"name":"Senior Department of Otolaryngology Head and Neck Surgery, The 6th Medical Center of Chinese PLA General Hospital, Chinese PLA Medical School, Beijing, China"},{"name":"National Clinical Research Center for Otolaryngologic Diseases, Beijing, China"},{"name":"State Key Laboratory of Hearing and Balance Science, Beijing, China"},{"name":"Key Laboratory of Hearing Science, Ministry of Education, Beijing, China"},{"name":"Beijing Key Laboratory of Hearing Impairment Prevention and Treatment, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6508-6816","authenticated-orcid":false,"given":"Xinxin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Senior Department of Otolaryngology Head and Neck Surgery, The 6th Medical Center of Chinese PLA General Hospital, Chinese PLA Medical School, Beijing, China"},{"name":"National Clinical Research Center for Otolaryngologic Diseases, Beijing, China"},{"name":"State Key Laboratory of Hearing and Balance Science, Beijing, China"},{"name":"Key Laboratory of Hearing Science, Ministry of Education, Beijing, China"},{"name":"Beijing Key Laboratory of Hearing Impairment Prevention and Treatment, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"2026072406201417000_14.7.e015325.1","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1017\/S0022215118000555","article-title":"Management of advanced hypopharyngeal carcinoma: systematic review of survival following surgical and non-surgical treatments","volume":"132","author":"Habib","year":"2018","journal-title":"J Laryngol Otol"},{"key":"2026072406201417000_14.7.e015325.2","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12031237","article-title":"Current Therapeutic Strategies for Patients with Hypopharyngeal Carcinoma: Oncologic and Functional Outcomes","volume":"12","author":"Bozec","year":"2023","journal-title":"J Clin Med"},{"key":"2026072406201417000_14.7.e015325.3","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1109417","article-title":"Survival analyses of different treatment modalities and clinical stage for hypopharyngeal carcinoma","volume":"13","author":"Lin","year":"2023","journal-title":"Front Oncol"},{"key":"2026072406201417000_14.7.e015325.4","doi-asserted-by":"crossref","DOI":"10.1186\/s12957-020-01866-z","article-title":"Treatment patterns and survival outcomes of advanced hypopharyngeal squamous cell carcinoma","volume":"18","author":"Tsai","year":"2020","journal-title":"World J Surg Oncol"},{"key":"2026072406201417000_14.7.e015325.5","doi-asserted-by":"crossref","first-page":"6571","DOI":"10.21873\/anticanres.11261","article-title":"Clinical Outcomes of Definitive and Postoperative Radiotherapy for Stage I-IVB Hypopharyngeal Cancer","volume":"36","author":"Shirai","year":"2016","journal-title":"Anticancer Res"},{"key":"2026072406201417000_14.7.e015325.6","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.1016\/S1470-2045(25)00020-8","article-title":"International consensus on laryngeal preservation strategies in laryngeal and hypopharyngeal cancer","volume":"26","author":"Ferrari","year":"2025","journal-title":"Lancet Oncol"},{"key":"2026072406201417000_14.7.e015325.7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.6097"},{"key":"2026072406201417000_14.7.e015325.8","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/88.13.890"},{"key":"2026072406201417000_14.7.e015325.9","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djp007"},{"key":"2026072406201417000_14.7.e015325.10","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0007"},{"key":"2026072406201417000_14.7.e015325.11","first-page":"773","article-title":"Efficacy of non-surgical comprehensive treatment for locally advanced hypopharyngeal carcinoma with cervical esophagus invasion","volume":"58","author":"Geng","year":"2023","journal-title":"Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi"},{"key":"2026072406201417000_14.7.e015325.12","first-page":"22","article-title":"Retrospective analysis on 77 cases of T4b hypopharyngeal carcinoma treated by non-surgical treatments","volume":"57","author":"Gu","year":"2022","journal-title":"Chinese Journal of Otorhinolaryngology Head and Neck Surgery"},{"key":"2026072406201417000_14.7.e015325.13","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-49121-3","article-title":"Camrelizumab-based induction chemoimmunotherapy in locally advanced stage hypopharyngeal carcinoma: phase II clinical trial","volume":"15","author":"Gong","year":"2024","journal-title":"Nat Commun"},{"key":"2026072406201417000_14.7.e015325.14","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1158\/1078-0432.CCR-23-2398","article-title":"Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial","volume":"30","author":"Ou","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026072406201417000_14.7.e015325.15","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105505","article-title":"Tislelizumab plus nab-paclitaxel and cisplatin as induction immunochemotherapy for organ preservation of locally advanced hypopharyngeal squamous cell carcinoma: a single-arm phase II trial","volume":"10","author":"Gui","year":"2025","journal-title":"ESMO Open"},{"key":"2026072406201417000_14.7.e015325.16","doi-asserted-by":"publisher","DOI":"10.21037\/apm.2017.03.05"},{"key":"2026072406201417000_14.7.e015325.17","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.38470","article-title":"Effect of Concurrent Chemoradiotherapy With Nedaplatin vs Cisplatin on the Long-term Outcomes of Survival and Toxic Effects Among Patients With Stage II to IVB Nasopharyngeal Carcinoma: A 5-Year Follow-up Secondary Analysis of a Randomized Clinical Trial","volume":"4","author":"Tang","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026072406201417000_14.7.e015325.18","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.6004\/jnccn.2019.7297","article-title":"Survival After Definitive Chemoradiotherapy With Concurrent Cisplatin or Carboplatin for Head and Neck Cancer","volume":"17","author":"Xiang","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"2026072406201417000_14.7.e015325.19","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S88023"},{"key":"2026072406201417000_14.7.e015325.20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2534"},{"key":"2026072406201417000_14.7.e015325.21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2554"},{"key":"2026072406201417000_14.7.e015325.22","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S0959-8049(01)00231-3","article-title":"EGFR and cancer prognosis","volume":"37 Suppl 4","author":"Nicholson","year":"2001","journal-title":"Eur J Cancer"},{"key":"2026072406201417000_14.7.e015325.23","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1200\/JCO.19.01981","article-title":"Epidermal Growth Factor Receptor Blockade in Head and Neck Cancer: What Remains?","volume":"37","author":"Jelinek","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026072406201417000_14.7.e015325.24","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.608","article-title":"Epidermal growth factor receptor\u2011targeted antibody nimotuzumab combined with chemoradiotherapy improves survival in patients with locally advanced head and neck squamous cell carcinoma: a propensity score matching real-world study","volume":"5","author":"Zhang","year":"2024","journal-title":"MedComm (2020)"},{"key":"2026072406201417000_14.7.e015325.25","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s40265-019-01076-2","article-title":"Toripalimab: First Global Approval","volume":"79","author":"Keam","year":"2019","journal-title":"Drugs"},{"key":"2026072406201417000_14.7.e015325.26","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.20181"},{"key":"2026072406201417000_14.7.e015325.27","doi-asserted-by":"crossref","first-page":"103890","DOI":"10.1016\/j.clon.2025.103890","article-title":"A Comparative Study of Initiated Chemotherapy Versus Initiated Surgery Combined with Primary-Radiotherapy in Locoregionally Advanced Hypopharyngeal Carcinoma","volume":"44","author":"Zhao","year":"2025","journal-title":"Clin Oncol"},{"key":"2026072406201417000_14.7.e015325.28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32591-7"},{"key":"2026072406201417000_14.7.e015325.29","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1200\/JCO.1994.12.8.1592","article-title":"Tumor response, toxicity, and survival after neoadjuvant organ-preserving chemotherapy for advanced laryngeal carcinoma. The Department of Veterans Affairs Cooperative Laryngeal Cancer Study Group","volume":"12","author":"Spaulding","year":"1994","journal-title":"J Clin Oncol"},{"key":"2026072406201417000_14.7.e015325.30","doi-asserted-by":"crossref","DOI":"10.1007\/s00432-024-06044-2","article-title":"Response to induction chemotherapy as a prognostic indicator in locally advanced head and neck squamous cell carcinoma","volume":"151","author":"Huwyler","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026072406201417000_14.7.e015325.31","doi-asserted-by":"crossref","first-page":"15330338221107714","DOI":"10.1177\/15330338221107714","article-title":"Tumor Volume Reduction Rate to Induction Chemotherapy is a Prognostic Factor for Locally Advanced Head and Neck Squamous Cell Carcinoma: A Retrospective Cohort Study","volume":"21","author":"Lin","year":"2022","journal-title":"Technol Cancer Res Treat"},{"key":"2026072406201417000_14.7.e015325.32","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1002\/cncr.32179","article-title":"A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer","volume":"125","author":"Patil","year":"2019","journal-title":"Cancer"},{"key":"2026072406201417000_14.7.e015325.33","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1312"},{"key":"2026072406201417000_14.7.e015325.34","doi-asserted-by":"crossref","DOI":"10.3892\/ol.2025.15142","article-title":"Dosimetric comparison and prognostic analysis of helical tomotherapy vs. intensity-modulated radiation therapy in locally advanced cervical cancer","volume":"30","author":"Xue","year":"2025","journal-title":"Oncol Lett"},{"key":"2026072406201417000_14.7.e015325.35","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.ijrobp.2017.06.2456","article-title":"Clinical Outcomes of Several IMRT Techniques for Patients With Head and Neck Cancer: A Propensity Score-Weighted Analysis","volume":"99","author":"Bibault","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026072406201417000_14.7.e015325.36","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00100-1"},{"key":"2026072406201417000_14.7.e015325.37","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30737-3"},{"key":"2026072406201417000_14.7.e015325.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.006"},{"key":"2026072406201417000_14.7.e015325.39","unstructured":"Committee CA-CAECP . n.d. Chinese Expert Consensus on Screening, Diagnosis and Treatment of Multiple Primary Cancers in the Lower Throat and Esophagus. Chinese Journal of Surgery. Available: https:\/\/cmab.yiigle.com\/uploads\/guide_html\/"},{"key":"2026072406201417000_14.7.e015325.40","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1221616","article-title":"Screening and surveillance of esophageal cancer by magnifying endoscopy with narrow band imaging improves the survival of hypopharyngeal cancer patients","volume":"13","author":"Chung","year":"2023","journal-title":"Front Oncol"},{"key":"2026072406201417000_14.7.e015325.41","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1711.2002.01057.x"},{"key":"2026072406201417000_14.7.e015325.42","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/cmi.2017.153","article-title":"CD8+CD28- T cells: not only age-related cells but a subset of regulatory T cells","volume":"15","author":"Chen","year":"2018","journal-title":"Cell Mol Immunol"},{"key":"2026072406201417000_14.7.e015325.43","doi-asserted-by":"publisher","DOI":"10.1152\/advan.00066.2013"},{"key":"2026072406201417000_14.7.e015325.44","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.20.100101.151926"},{"key":"2026072406201417000_14.7.e015325.45","doi-asserted-by":"crossref","first-page":"563653","DOI":"10.3389\/fimmu.2020.563653","article-title":"Pretreatment Peripheral B Cells Are Associated With Tumor Response to Anti-PD-1-Based Immunotherapy","volume":"11","author":"Yuan","year":"2020","journal-title":"Front Immunol"},{"key":"2026072406201417000_14.7.e015325.46","doi-asserted-by":"publisher","DOI":"10.1038\/nm0598-627"},{"key":"2026072406201417000_14.7.e015325.47","doi-asserted-by":"crossref","first-page":"113197","DOI":"10.1016\/j.intimp.2024.113197","article-title":"Neoadjuvant chemoimmunotherapy for laryngeal preservation in locally advanced hypopharyngeal cancer","volume":"142","author":"Pan","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"2026072406201417000_14.7.e015325.48","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1007\/s00262-023-03550-z","article-title":"PD-1 Inhibitors combined with paclitaxel (Albumin-bound) and cisplatin for larynx preservation in locally advanced laryngeal and hypopharyngeal squamous cell carcinoma: a retrospective study","volume":"72","author":"Fang","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"2026072406201417000_14.7.e015325.49","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-023-03579-0","article-title":"Retrospective assessment of neoadjuvant camrelizumab combined with induction chemotherapy: efficacy in laryngeal preservation for advanced hypopharyngeal and laryngeal squamous cell carcinoma","volume":"73","author":"Peng","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"2026072406201417000_14.7.e015325.50","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1007\/s10637-024-01456-w","article-title":"Neoadjuvant immunochemotherapy in locally advanced laryngeal cancer and hypopharyngeal cancer: higher objective response rate and organ-preservation rate","volume":"42","author":"Chen","year":"2024","journal-title":"Invest New Drugs"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2026-015325","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:20:29Z","timestamp":1784899229000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2026-015325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":50,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,24]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/jitc-2026-015325"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2026-015325","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}